Asymmetric synthesis of an important precursor to 5′-nor carbocyclic nucleosides
作者:Paul F. Vogt、Jan-Gerd Hansel、Marvin J. Miller
DOI:10.1016/s0040-4039(97)00511-x
日期:1997.4
4R)-4-[N-(tert-butoxycarbonyl)amino]-2-cyclopentene-1-ol (4). The amino acid chiral auxiliary was removed by the Edman degradation. This enantiomerically pure aminoalcohol is a key intermediate in the synthesis of 5′-nor carbocyclic nucleosides.
The present invention relates to new cyclopropyl modulators of P2Y12 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.
本发明涉及P2Y12受体活性的新环丙基调节剂,其制药组合物以及使用方法。
DEUTERATED DERIVATIVES OF TICAGRELOR FOR MEDICAL USE
申请人:Auspex Pharmaceuticals, Inc.
公开号:EP3135675A1
公开(公告)日:2017-03-01
The present invention relates to deuterated compounds having a modulatory activity at the P2Y12 receptor for use in the treatment of myocardial infarction, stroke or acute coronary syndrome.
本发明涉及具有调节P2Y12受体活性的氘代化合物,用于治疗心肌梗死、中风或急性冠状动脉综合征。
Compositions Having Antimycrobial Activity Including a Hydroxamate or a Hydroxamate and a Hydroxlyamine
申请人:Kohn Harold
公开号:US20080249181A1
公开(公告)日:2008-10-09
Antimycorbacterial compositions are disclosed comprising at least one hydroxamate or at least one hydroxamate and at least one hydroxylamine. The preferred ratio of hydroxamate to hydroxylamines is about 100:1 to about 1:1. A method for inhibiting mycobacterial growth is also disclosed comprising the step of administering the compositions of this invention to an animal including a human.
The present invention relates to new cyclopropyl modulators of P2Y12 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.